Morgan Stanley analyst, Jeffrey Hung, reiterated his Equalweight rating on shares of Ultragenyx Pharma (NASDAQ: RARE) and cut his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE